Exelixis, Inc. (EXEL) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Alameda, CA, 美国. 現任CEO為 Michael Morrissey.
EXEL 擁有 IPO日期為 2000-04-17, 1,147 名全職員工, 在 NASDAQ Global Select, 市值為 $12.3B.
Exelixis, Inc. is an oncology-focused biotechnology company engaged in the discovery, development, and commercialization of cancer treatments. The company's marketed products include CABOMETYX for advanced renal cell carcinoma, COMETRIQ for medullary thyroid cancer, COTELLIC for advanced melanoma, and MINNEBRO for hypertension in Japan. Exelixis maintains an active pipeline of investigational therapies, including XL092, XB002, and XL102, which target various cancer mechanisms through tyrosine kinase inhibition and other novel pathways. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Ipsen, Takeda, Roche, and Bristol-Myers Squibb to advance its research and development efforts. Headquartered in Alameda, California, Exelixis was founded in 1994 and operates globally in the oncology market.
